Heart Failure

The Heart Failure pipeline: 74 tracked drugs, 12 approved for this indication.

12 approved / phase 419 Phase 32 Phase 2/322 Phase 25 Phase 1/212 Phase 12 preclinical / unstaged

Compare the share prices of listed companies in Heart Failure →

Total attributable cost

$27.7B

$3,594/patient

Drug spend

Not yet sourced

How this is calculated ↗

All severities (2021-2023 NHANES cycle) · US

The Heart Failure pipeline

Key trial results for every approved and late-stage drug: Heart Failure results by drug.

← all assets